R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Is biotech ready for the lecanemab opportunity?

The US Veterans Health Administration recently announced that it will cover the cost of Biogen’s lecanemab for veterans suffering from early stages of Alzheimer’s disease.

R&D

Making accessibility strategy part of your rare disease tria...

Over the past several years, diversity, equity, and inclusion (DEI) has become a central subject of conversation in clinical trials.

R&D

Why Ireland has emerged as Europe’s biopharma hotspot

Ireland is attracting major investment from the largest pharma companies in the world.

R&D

Creating healthier futures - Reuters Pharma Barcelona 2023

In this latest mini pharmaphorum podcast, web editor Nicole Raleigh spoke with Tommy Bramley, SVP of global consulting at Amerisource Bergen, whilst attending Reuters Pharma Barcelona.

R&D

Reuters Pharma USA – Lung-I Cheng

Cell and gene therapies continue to be hot topics in the pharma world this year, and some companies are responding to the new treatment modalities with new business units.

R&D